Leonardo Nicacio

ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.

Aditya Bardia, Virginia Kaklamani, Joyce O’Shaughnessy, Peter Schmid et autres

us, gb, it, be (code pays fourni par la source)

P439: ELEGANT: Elacestrant vs Standard ET in Women and Men With Node-positive, ER+, HER2- Early Breast Cancer (eBC) With High Risk of Recurrence – A Global, Multicenter, Randomized, Openlabel Phase 3 Study

A. Bardia, V. Kaklamani, J. O'Shaughnessy, Peter Schmid et autres

Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.

Lova Sun, Jérôme Fayette, Sébastien Salas, David S. Hong et autres

us, fr, it, es, br (code pays fourni par la source)

681 innovaTV 207 Parts E and F: a phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress)

Tanguy Y. Seiwert, Lara Dunn, Lova Sun, Thomas J. George et autres

us (code pays fourni par la source)

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Ignace Vergote, Els Van Nieuwenhuysen, Roisin E. O’Cearbhaill, Anneke M. Westermann et autres

be, us, nl, it, ie, gb, fr, in, sg, br, se, ch, jp, cz, dk, tr (code pays fourni par la source)

Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

Chaitali Passey, Jenna L. Voellinger, Leonid Gibiansky, Rudy Gunawan et autres

us (code pays fourni par la source)

Abstract CT164: Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207

Beatriz Cirauqui, Sébastien Salas, William William, Ariel E. Birnbaum et autres

es, fr, br, us, it (code pays fourni par la source)

Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study

Kan Yonemori, Yasutoshi Kuboki, Kosei Hasegawa, Takashi Iwata et autres

jp, us, dk (code pays fourni par la source)

Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results From a Phase II Cohort

D.S. Hong, Ariel E. Birnbaum, Conor E. Steuer, Matthew H. Taylor et autres

us (code pays fourni par la source)

O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results

Bradley J. Monk, Toon Van Gorp, Domenica Lorusso, R.E. O’Cearbhaill et autres

us, be, it, nl, gb, ie, cz, dk (code pays fourni par la source)

Tisotumab Vedotin + Carboplatin in First-Line or + Pembrolizumab in Previously Treated Recurrent/Metastatic Cervical Cancer: Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205

I. Vergote, B.J. Monk, R.E. O’Cearbhaill, Anneke M. Westermann et autres

be (code pays fourni par la source)

930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors

David S. Hong, Jérôme Fayette, Ariel E. Birnbaum, Conor Steuer et autres

us, fr, dk (code pays fourni par la source)